Literature DB >> 308040

Identification, functional characterization and partial purification of thymus-derived lymphocytes in inbred hamsters.

J W Blasecki, K J Houston.   

Abstract

Antiserum specific for hamster thymus-derived lymphocytes, prepared by immunization of rabbits with brain tissue from MHA/ssLAK hamsters, was, in the presence of guinea-pig complement, cytotoxic to hamster thymocytes greater than lymph node cells greater than spleen cells, while virtually unreactive against bone marrow cells. This antiserum markedely inhibited spleen cell response to the T cell mitogen, Concanavalin A, while the response to the B the T cell mitogen, pokeweed, was much less inhibited. These in vitro effects of the anti-hamster T cell serum were confirmed by utilizing lymphoid cells from thymectomized, lethally-irradiated, bone marrow-reconstituted hamsters. Lymph node cells from such animals were killed by the anti-T cell serum only to the same extent as bone marrow cells, while spleen cells from these animals gave a good response to pokeweek mitogen but were virtually unresponsive to Concanavalin A. Passage of hamster spleen cells over nylon wool columns yielded effluent populations highly enriched in T lymphocytes. The eluted cells were fully capable of T cell functions, as determined by their blastogenic response to various T and B cell mitogens in vitro and their ability to inhibit the growth of syngeneic SV40 tumours in vivo.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 308040      PMCID: PMC1457237     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  17 in total

1.  B-cell origin of hamster lymphoid tumors induced by simian virus 40.

Authors:  J E Coe; I Green
Journal:  J Natl Cancer Inst       Date:  1975-01       Impact factor: 13.506

2.  Resistance of macrophages from C3H/HeJ mice to the in vitro cytotoxic effects of endotoxin.

Authors:  L M Glode; A Jacques; S E Mergenhagen; D L Rosenstreich
Journal:  J Immunol       Date:  1977-07       Impact factor: 5.422

3.  Mitogens as probes for immunocyte activation and cellular cooperation.

Authors:  J Andersson; O Sjöberg; G Möller
Journal:  Transplant Rev       Date:  1972

4.  Chemical carcinogenesis in Syrian hamsters.

Authors:  F Homburger
Journal:  Prog Exp Tumor Res       Date:  1972

5.  Requirement of thymus-derived theta-positive lymphocytes for rejection of DNA virus (SV 40) tumors in mice.

Authors:  S S Tevethia; J W Blasecki; G Waneck; A L Goldstein
Journal:  J Immunol       Date:  1974-11       Impact factor: 5.422

6.  Immunoglobulins of the hamster. I. Antibody activity in four immunoglobulin classes.

Authors:  J Bienenstock; K J Bloch
Journal:  J Immunol       Date:  1970-05       Impact factor: 5.422

7.  In vitro assay of cellular immunity to tumor-specific antigen(s) of virus-induced tumors by macrophage migration inhibition.

Authors:  J W Blasecki; S S Tevethia
Journal:  J Immunol       Date:  1973-02       Impact factor: 5.422

8.  An analysis of graft-versus-host disease in Syrian hamsters. I. The epidermolytic syndrome: description and studies on its procurement.

Authors:  J W Streilein; R E Billingham
Journal:  J Exp Med       Date:  1970-07-01       Impact factor: 14.307

9.  THE AKR THYMIC ANTIGEN AND ITS DISTRIBUTION IN LEUKEMIAS AND NERVOUS TISSUES.

Authors:  A E REIF; J M ALLEN
Journal:  J Exp Med       Date:  1964-09-01       Impact factor: 14.307

10.  Occurrence of a theta-like antigen in rats.

Authors:  T C Douglas
Journal:  J Exp Med       Date:  1972-11-01       Impact factor: 14.307

View more
  2 in total

1.  Ability of enriched immune T cells to confer resistance in hamsters to infection with Treponema pertenue.

Authors:  J K Chan; R F Schell; J L LeFrock
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

2.  Hamster T cells participate in MHC alloimmune reactions but do not effect virus-induced cytotoxic activity.

Authors:  M J Nelles; J W Streilein
Journal:  Immunogenetics       Date:  1980-07       Impact factor: 2.846

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.